Prospective, multicentre trial evaluating FET-PET in Glioblastoma

The FIG trial is investigating how the addition of FET-PET imaging to standard MRI imaging affects radiation target volume delineation and treatment planning for Glioblastoma, as well as determining the accuracy and management impact of FET-PET in distinguishing pseudoprogression from true tumour progression and / or tumour recurrence.

Primary Sponsor

Trans Tasman Radiation Oncology Group (TROG)

Collaborating Groups

COGNO, ARTnet, ONJCRI

Participating Centres

Accrual Target

210

Current Accrual

Expected Date of Accrual

31 December 2024

Trial Chairperson

Prof Andrew Scott, Olivia Newton-John Cancer Research Institute (ONJCRI) / The Austin Health, VIC, Australia

A/Prof Eng-Siew Koh, Liverpool Hospital, NSW, Australia

Trial Contact

FIG@trog.com.au

Clinical Trial Registration

Related Post

Yu Yang Soon, TROG Lung Working Party
31 July, 2025

World Lung Cancer Day: Focus on the TROG Lung Working Party

TROG WORKING PARTY IN FOCUS: 31 July 2025 To

29 July, 2025

TROG 21.07 SOCRATES HCC Trial Expands Outreach

TRIAL IN FOCUS: 29 July 2025 We’ve extended the